Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Cognitive Functioning in Bipolar Patients Receiving Lamotrigine: Preliminary Results

Daban, Claire PhD; Martínez-Arán, Anabel PhD; Torrent, Carla PsyD; Sánchez-Moreno, Jose PsyD; Goikolea, Jose Manuel MD; Benabarre, Antonio MD; Comes, Merce PsN; Colom, Francesc PhD; Vieta, Eduard MD, PhD

Journal of Clinical Psychopharmacology: April 2006 - Volume 26 - Issue 2 - p 178-181
doi: 10.1097/01.jcp.0000204332.64390.f3
Brief Reports

Abstract: Despite the increasing use of lamotrigine (LTG) in bipolar disorder, little is known about its impact on cognition in bipolar patients. Therefore, we have evaluated 33 bipolar I and II patients on cognitive measures (verbal memory, attention, executive functions) while receiving either LTG (n = 15) or another anticonvulsant (carbamazepine or valproate; n = 18). Patients receiving LTG were generally diagnosed as having bipolar II disorder, had experienced more depressive episodes but a lesser number of hospitalizations, and had better performance than the patients receiving carbamazepine or valproate on the verbal fluency task. A moderate effect size also suggests that both groups may differ on the immediate verbal memory test (California Verbal Learning Test). These preliminary results suggest a safer neurocognitive profile of LTG on bipolar patients, as compared with other anticonvulsants.

Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.

Received July 6, 2005; accepted after revision January 4, 2006.

This research was funded by a Stanley Medical Research Institute Center grant.

Address correspondence and reprint requests to Eduard Vieta, MD, PhD, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain. E-mail: evieta@clinic.ub.es.

© 2006 Lippincott Williams & Wilkins, Inc.